157 related articles for article (PubMed ID: 28450784)
21. Concomitant blockade of A2AR and CTLA-4 by siRNA-loaded polyethylene glycol-chitosan-alginate nanoparticles synergistically enhances antitumor T-cell responses.
Ghasemi-Chaleshtari M; Kiaie SH; Irandoust M; Karami H; Nabi Afjadi M; Ghani S; Aghaei Vanda N; Ghaderi Sede MJ; Ahmadi A; Masjedi A; Hassannia H; Atyabi F; Hojjat-Farsangi M; Namdar A; Ghalamfarsa G; Jadidi-Niaragh F
J Cell Physiol; 2020 Dec; 235(12):10068-10080. PubMed ID: 32488862
[TBL] [Abstract][Full Text] [Related]
22. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
23. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma.
Ruehlmann JM; Xiang R; Niethammer AG; Ba Y; Pertl U; Dolman CS; Gillies SD; Reisfeld RA
Cancer Res; 2001 Dec; 61(23):8498-503. PubMed ID: 11731434
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
Jovanovic IP; Pejnovic NN; Radosavljevic GD; Pantic JM; Milovanovic MZ; Arsenijevic NN; Lukic ML
Int J Cancer; 2014 Apr; 134(7):1669-82. PubMed ID: 24105680
[TBL] [Abstract][Full Text] [Related]
25. MULT1E/mIL-12: a novel bifunctional protein for natural killer cell activation.
Tietje A; Li J; Yu X; Wei Y
Gene Ther; 2014 May; 21(5):468-75. PubMed ID: 24572784
[TBL] [Abstract][Full Text] [Related]
26. IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors.
Zhu S; Lee DA; Li S
J Immunol; 2010 Mar; 184(5):2348-54. PubMed ID: 20139275
[TBL] [Abstract][Full Text] [Related]
27. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
[TBL] [Abstract][Full Text] [Related]
29. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70.
Bae JH; Kim JY; Kim MJ; Chang SH; Park YS; Son CH; Park SJ; Chung JS; Lee EY; Kim SH; Kang CD
J Immunother; 2010 May; 33(4):391-401. PubMed ID: 20386467
[TBL] [Abstract][Full Text] [Related]
30. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
[TBL] [Abstract][Full Text] [Related]
32. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.
Xiang R; Lode HN; Dolman CS; Dreier T; Varki NM; Qian X; Lo KM; Lan Y; Super M; Gillies SD; Reisfeld RA
Cancer Res; 1997 Nov; 57(21):4948-55. PubMed ID: 9354462
[TBL] [Abstract][Full Text] [Related]
33. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
34. Delivery of platinum(IV) drug to subcutaneous tumor and lung metastasis using bradykinin-potentiating peptide-decorated chitosan nanoparticles.
Wang X; Yang C; Zhang Y; Zhen X; Wu W; Jiang X
Biomaterials; 2014 Aug; 35(24):6439-53. PubMed ID: 24811257
[TBL] [Abstract][Full Text] [Related]
35. Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer.
Tamura T; Nishi T; Goto T; Takeshima H; Dev SB; Ushio Y; Sakata T
Hum Gene Ther; 2001 Jul; 12(10):1265-76. PubMed ID: 11440620
[TBL] [Abstract][Full Text] [Related]
36. NKG2D ligands expression and NKG2D-mediated NK activity in Sezary patients.
Dulphy N; Berrou J; Campillo JA; Bagot M; Bensussan A; Toubert A
J Invest Dermatol; 2009 Feb; 129(2):359-64. PubMed ID: 18754036
[TBL] [Abstract][Full Text] [Related]
37. Bone-protective effects of nonviral gene therapy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis.
Fernandes JC; Wang H; Jreyssaty C; Benderdour M; Lavigne P; Qiu X; Winnik FM; Zhang X; Dai K; Shi Q
Mol Ther; 2008 Jul; 16(7):1243-51. PubMed ID: 18500247
[TBL] [Abstract][Full Text] [Related]
38. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
[TBL] [Abstract][Full Text] [Related]
39. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
[TBL] [Abstract][Full Text] [Related]
40. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice.
Hirahara N; Nio Y; Sasaki S; Minari Y; Takamura M; Iguchi C; Dong M; Yamasawa K; Tamura K
Oncology; 2001; 61(1):79-89. PubMed ID: 11474253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
